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Background: Recent data indicate that the cell adhesion proteins are abnormally regulated in several human
cancers and the expression of the cell adhesion proteins E-cadherin and claudin proteins is involved in the
etiology and progression of cancer. It is clear that these protein represent promising targets for cancer
detection, diagnosis, and therapy.
Methods: To explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin
in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of
adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and
E-cadherin by streptavidin-perosidase immunohistochemical staining method.
Results: The positive expression rates of E-cadherin in gastric cancer tissues and adjacent non-neoplastic tissues
were 32% and 74% respectively (P < 0.01). The positive expression rates of claudin-10 in gastric cancer tissues
and adjacent non-neoplastic tissues were 24% and 72% respectively (P < 0.01). The positive expression rates of
claudin-17 in gastric cancer tissues and adjacent non-neoplastic tissues were 18% and 70% (P < 0.01). In contrast,
the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were
58% and 24% respectively (P = 0.015 < 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and
claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.
Correlations between claudins and E-cadherin expression with lymphatic metastasis were observed.
Conclusion: Our study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were
down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation
between claudins and E-cadherin expression with lymphatic metastasis were observed.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/1475928069111326.
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ImmunohistochemistryIntroduction
Cell-cell adhesion junction is an essential necessity during
cell differentiation, tissue development, and tissue homeo-
stasis [1]. It is reported that the development of malignant
tumors, in particular the transition from benign lesions to
invasive, metastatic cancer, is characterized by a tumor
cell’s ability to overcome cell-cell adhesion and to invade* Correspondence: guanjunwang2006@163.com
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stated.surrounding tissue and loss of cell-cell adhesion is dis-
played in many cancers and correlates with metastasis and
poor prognosis [2]. Many different cell-adhesion mole-
cules are implicated in human carcinogenesis [3]. During
the transition from normal cells to highly malignant tumor
cells, the expression of some of these adhesion molecules
is switched off, whereas that of others is induced. E-
cadherin, a transmembrane adhesion protein, is the major
constituents of the epithelial cell junction system [4]. Be-
sides E-cadherin exerts a potent invasion-suppressing role. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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and loss of E-cadherin expression during tumor progres-
sion has been observed in numerous human carcinomas
[5]. It is revealed that DNA hypermethylation and chro-
matin rearrangements within the regulatory regions of the
E-cadherin gene have been correlated with the loss of E-
cadherin expression in primary hepatocellular and breast
carcinomas [6-8]. Other observations suggest that the loss
of E-cadherin transcription in cancer cells is primarily due
to transacting pathways regulating E-cadherin gene ex-
pression [9,10]. Besides supporting cell-cell adhesion, E-
cadherin can affect a wide range of cellular functions that
include activation of cell signaling pathways, regulation of
the cytoskeleton and control of cell polarity [11-13].
Tight junctions, together with adherent junctions and
desmosomes, form the apical junction complex in epithe-
lial and endothelial cellular sheets [14-16]. The claudin
protein family have a crucial role in formation of tight
junctions (TJs), and consists of approximately 27 mem-
bers, which are expressed with a tissue-specific distribu-
tion [17]. Because of the ability of tight junction proteins
to recruit signaling proteins, tight junctions have also been
hypothesized to be involved in the regulation of prolifera-
tion, differentiation, and other cellular functions [18,19].
Malignant cells not only accompanied with cell-adhesion
abnormity but also frequently display structural and func-
tional disruption of the tight junctions [20]. Recently, the
abnormal expression of members of the claudin protein
family has been reported to participate in tumorigenesis
[21,22]. In particular, claudin-3 and claudin-4 are fre-
quently overexpressed in several neoplasias, including
ovarian, breast, pancreatic, and prostate cancers [23].
Moreover, claudin-4 protein is significantly up-regulated in
breast invasive ductal carcinomas and is an important cor-
relate with lymphatic metastasis [24]. Although the exact
roles of these proteins in tumorgenesis are still being un-
covered, it appears that claudin expression has significance
during tumor progression [25]. Claudin-5 has been seen in
a proportion of gastric carcinomas and seemed to be posi-
tively associated with biological markers associated with
tumor growth, such as proliferation and apoptosis [26]. It
is clear that they represent promising targets for cancer de-
tection, diagnosis, and therapy.
In general, expression of different claudins has not been
extensively studied in human tissues and in tumors [27].
An early study in the field showed that occludin was
often down-regulated in gastrointestinal tumors [28] and
claudin-10 has been found to be reduced in breast cancer
as well as in colon cancer [29]. Besides, loss of claudin-17
appears to be associated with a more aggressive behavior of
breast carcinoma [30]. These reports of decreased tight
junction protein expression in cancer are consistent with
the generally accepted idea that tumorigenesis is accom-
panied by a disruption of tight junctions, a process thatmay play an important role in the loss of cohesion, inva-
siveness, and lack of differentiation observed in cancer
cells. In addition to the up-regulation or down-regulation
of protein levels, phosphorylation of tight junction proteins,
including claudins, may affect tight junction function in
cancer. Interestingly, phosphorylation of claudin-3 and
claudin-4 in ovarian cancer cells has been shown to disrupt
tight junctions [31,32]. Paradoxically, other studies have
shown that certain claudin proteins are up-regulated in
cancer. Overexpression of claudin-3 and −4 has been
shown in ovarian carcinoma [33]. In addition, claudin-3
and claudin-4 have also been reported to be expressed in
other cancers, such as prostate, and pancreatic cancers [34].
It has been reported that the expression of claudin-2
and claudin-6 was reduced whereas the expression of
claudin-11 in gastric cancer was increased in comparison
with gastric adjacent non-neoplastic tissues [35]. Claudin-
18 gene and claudin-23, frequently down-regulated in
intestinal-type gastric cancer and has been shown to have
prognostic value in gastric cancer [36]. In summary, in
gastric cancer, claudin protein expression has been dem-
onstrated to be of great importance and a relevant area for
further study. It is revealed that E-cadherin is specifically
required for tight junction formation, but not desmosome,
and this appears to involve signaling rather than cell con-
tact formation [37]. Thus, the objective of this study was
to examine the expression of claudin-10,-14, -17 and E-
cadherin in gastric carcinoma and adjacent tissue which
have been less well studied. We used immunohistochemi-
cal staining to explore the expression of these proteins in
gastric cancer and adjacent non-neoplastic tissues, and




There were 50 cases of gastric cancer and 50 cases of his-
tologically normal adjacent non-neoplastic tissues taken
out at more than 2 cm from the tumors were collected
from patients being treated at the First Hospital of Jilin
University during the period between August 2011 and
May 2012. The patients’ medical records were reviewed to
determine their age and gender. Sections of the primary
tumor were analyzed to identify the histological grade, and
the presence or absence of regional lymph node metasta-
sis. There were 34 men and 16 women with average age of
49 years. The cases consisted of 14 well differentiated, 25
moderately differentiated and 11 poor differentiated histo-
logical appearance tumors. For the use of these clinical
materials for research purposes, prior patient’s consent
and approval from the Institute Research Ethics Commit-
tee was obtained. All the cancer cases were classified
and graded according to the International Union against
Cancer (UICC) staging system for gastric cancer.
Table 1 Expression of E-cadherin and clinicopathological
characteristics in gastric cancer patients
Item n E-cadherin (+) E-cadherin (−) P
Gastric cancer tissue 50 16 34 <0.01
Adjacent tissue 50 37 13
Gender
Male 34 10 24 0.494*
Female 16 6 10
Age (year)
≤60 26 8 18 1.000*
>60 24 8 16
Histological grade
Well – differentiated 14 8 6 <0.01
Moderately differentiated 25 7 18
Poor differentiated 11 1 10
Lymph node metastasis
+ 24 4 20 <0.01
- 26 12 14
Ki67
+ 17 6 11 0.356*
- 33 10 23
*No statistical significance.
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Rabbit monoclonal antihuman E-Cadherin antibody
(ab40772), Rabbit polyclonal to claudin-10 antibody
(ab66053), Goat polyclonal to claudin-14 antibody
(ab115868), Rabbit polyclonal to claudin-17 antibody
(ab23333) were purchased from Abcam Technology
(USA) and an streptavidin-perosidase immunohisto-
chemistry reagent kit were purchased from Maixin
Biology (Fujian, China).
Criteria for the positive claudin-10,-14 -17 and E-cadherin
expression in tissue
The cells positively expressing claudin-10, -14 -17 and E-
cadherin were identified by brown staining of cell
membrane after reaction with claudin-10, -14,-17 and
E-cadherin antibody. The claudin-10,-14,-17 positive
tissues were quantified based on the percentage of
positive cells which were serially counted in one micro-
scopic field. The cell counting was repeated in five
randomly-selected microscopic fields at × 400 magnifica-
tion. The E-cadherin negative group contained less than
15% positive cells and the positive group, more greater
than 15%. The claudin-10 negative groups were defined as
a field with level less than 10% (of the tumor cells); posi-
tive groups had more than 10% positive cells. The claudin-
14 negative group had less than 10% stained cells and the
positive group more than 10%. The claudin-17 negative
group contained less than 20% positive cells and the posi-
tive group, more greater than 20%.
Statistical analysis
The Chi-square test/Chi-Square Goodness-of-Fit Test
was used to determine the prognostic significance
value for disease progression of each factor alone,
using a P-value < 0.05 for statistically significant associ-
ations. All the data were analyzed using SPSS 12.0 stat-
istical software.
Results
Population and tumor characteristics
The clinicopathological characteristics of the patients
are summarized in Table 1.
The expression of claudin-10, claudin-17 and E-cadherin
was reduced in gastric cancer
In our study, E-cadherin expression was evaluated in
the membranes of 50 gastric cancers tissues and 50
specimens containing gastric tissue adjacent to the car-
cinoma. Positive expression of E-cadherin protein was
found in 32.0% (16/50) of gastric carcinoma tissues
and in 74% (37/50) of adjacent tissues (Table 1). The
expression of E-cadherin in gastric cancer tissues was
significantly lower than in adjacent tissues (The Chi-
square test/Chi-Square Goodness-of-Fit Test, P < 0.01)(Figure 1A, B). As shown in Table 1 the expression of
E-cadherin was not correlated with age (P =1.000), sex
(P =0.494), expression of Ki 67 (P =0.356) but corre-
lated with histological grade (P < 0.01) and lymph node
metastasis (P < 0.01).
Positive expression of claudin-10 protein was found in
24.0% (12/50) of gastric carcinoma tissues and in 72% (36/
50) of adjacent tissues (Table 2). The expression of
claudin-10 in gastric cancer tissues was significantly lower
than in adjacent tissues (The Chi-square test/Chi-Square
Goodness-of-Fit Test, P < 0.01) (Figure 1C, D). As shown
in Table 2 the expression of claudin-10 was not correlated
with age (P =1.000), sex (P =0.664), histological grade (P =
1.000), expression of Ki 67(P =0.464) but correlated with
lymph node metastasis (P < 0.01) and expression of E-
cadherin (P < 0.01).
Positive expression of claudin-17 protein was found in
18.0% (9/50) of gastric cancer tissues and in 70.0% (35/
70) of adjacent tissues (Table 2). The expression rate of
claudin-17 in gastric cancer tissues was lower than the
rate in adjacent tissues (The Chi-square test/Chi-Square
Goodness-of-Fit Test, P < 0.01) (Figure 1G, H). As
shown in Table 2 the expression of claudin-17 was not
correlated with age (P =0.677), sex (P =0.475), histo-
logical grade (P = 1.000), expression of Ki 67(P =0.633)
lymph node metastasis (P < 0.05) but correlated with ex-
pression of E-cadherin (P < 0.01).
Figure 1 Immunohistochemical demonstration of claudins protein and E-cadherin expression in human gastric cancer and adjacent
tissue. Claudins and E-cadherin were expressed in the cell membrane. (A), high E-Cadherin expression was detected in tissue adjacent to human
gastric cancer compared with low E-Cadherin expression in human gastric cancer tissue (B) (400×) (C), claudin-10 was highly expressed in
epithelial cells adjacent to gastric cancer but was expressed at low levels in cancer tissue itself (D). (E), the low expression of claudin-14 in tissue
adjacent to human gastric cancer compared to strong expression of claudin-14 in human gastric cancer tissue (F). (G), high claudin-17 expression
was detected in tissue adjacent to human gastric cancer compared with low claudin-17 expression in human gastric cancer tissue (H) (400×).
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gastric cancer
The membrane staining of claudin-14 was strong in gastric
cancer tissues and weak in adjacent tissues. Claudin-14 was
expressed in 58.0% (29/50) of gastric cancer tissues. Cells
were positive for claudin-14 in 24.0% (12/50) of tissues ad-
jacent to the cancer. We conclude that claudin-14 expres-
sion is significantly higher (Figure 1E, F) in gastric cancer
samples than in histologically normal gastric tissue. (The
Chi-square test/Chi-Square Goodness-of-Fit Test, P < 0.01).As shown in Table 2 the expression of claudin-17 was not
correlated with age (P =1.000), sex (P =0.355), histological
grade (P = 0.641), expression of Ki 67 (P =1.000) but corre-
lated with lymph node metastasis (P < 0.01) and negatively
related with expression of E-cadherin (P < 0.05).
Claudin-10, and claudin-14 were concurrently expressed
in gastric cancer
We investigated the correlation between claudin-10,
claudin-14 and claudin-17 expression using The Chi-
Table 2 Expression of CLAUDIN-10, CLAUDIN-14, CLAUDIN-17 and clinic pathological characteristics in gastric cancer patients
Item n CLAUDIN-10(+) CLAUDIN-10(−) P n CLAUDIN-14(+) CLAUDIN-14(−) P n CLAUDIN-17(+) CLAUDIN-17(−) P
Gastric cancer tissue 50 12 38 <0.01 50 29 21 <0.01 50 9 41 <0.01
Adjacent tissue 50 36 14 50 12 38 50 35 15
Gender
Male 34 8 28 0.664* 34 20 14 0.355* 34 7 27 0.475*
Female 16 4 12 16 9 7 16 2 14
Age(year)
≤60 26 7 19 1.000* 26 15 11 1.000* 26 4 22 0.677*
>60 24 5 19 24 14 10 24 5 19
Histological grade
Well –differentiated 14 4 10 1.000* 14 6 8 0.641* 14 3 11 1.000*
Moderately differentiated 25 7 18 25 15 10 25 5 20
Poor differentiated 11 1 10 11 8 3 11 1 10
Lymph node metastasis
+ 24 3 21 <0.01 24 18 6 <0.05 24 2 22 <0.05
- 26 9 17 26 11 15 26 7 19
E-cadherin
+ 16 9 7 <0.0 7 9 16 6 10 <0.01
- 3 1 16 22 12 <0.05 34 3 31
Ki67 31
+ 5 34 9 8 17 4 13 0.633*
- 34 7 12 0.464* 13 5 28
26 1.000*
17 17
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find a correlation between claudin-17 and claudin-10 (The
Chi-square test/Chi-Square Goodness-of-Fit Test, φ =
0.693, P <0.01) or with claudin-14 (The Chi-square test/
Chi-Square Goodness-of-Fit Test, φ = 0.124, P = 0.695), we
have not find that the expression of claudin-10 correlated
with the expression of claudin-14 (The Chi-square test/
Chi-Square Goodness-of-Fit Test, φ =0.164, P = 0.516). The
detailed results of the analysis are described in Table 3.
Discussion
The majority of human cancers originate from epithelial
cells. Normally, epithelial cells are tightly interconnected
through several junction structures, including tight junc-
tions, adherents-type junctions and desmosomes, which
are intimately associated with the actin and intermediate
cytoskeleton. Including carcinomas of the breast, colon,
prostate, liver, skin, kidney and lung appear to cause the
loss of E-cadherin function, caused by several different
mechanisms including deletion or mutational inactiva-
tion of the E-cadherin gene [38]. Notably, mutations in
the E-cadherin gene are evident in cases of familial gas-
tric cancers, which indicates that mutation of the E-
cadherin gene is sufficient to predispose individuals to
the development of malignant cancer. Moreover, the loss
of E-cadherin impair E-cadherin-mediated cell-cell adhe-
sion and E-cadherin contributes to epidermal barrier for-
mation by regulating the incorporation of claudins into
tight junctions and is specifically required for correct
tight junction formation [39].
Although the normal ratio of claudin proteins has a role
in maintaining the structure and function of tight junc-
tions in epithelial cells, the mechanisms by which claudins
expression and destruction of tight junctions induce
tumor formation and the effect of these changes on tumor
progression have not been studied in detail [40]. It has
been postulated that both abnormal expression and phos-
phorylation of claudin proteins would cause the structural
and functional disruption of tight junctions [41]. Cur-
rently, it is reported that the alternation of claudins ex-
pression is one of the mechanisms responsible for loss of
cell adhesion, altered polarity, poor differentiation andTable 3 Correlation between the expression of claudin-10, cla
Item CLAUDIN-10(+) CLAUDIN-10(−) φ*






*φ Phi coefficient.increased invasive potential of neoplastic cells [42]. In this
study, expression of claudin-10, 14, 17 and was studied in
50 cases of gastric carcinoma and adjacent non-neoplastic
tissues adjacent to the gastric carcinoma tissues. The re-
sults show variable and heterogenous expression of
claudin-10, -14 and-17 in gastric carcinoma. The most
prominent expression of claudins was seen for claudins-
14, where about 58% of cases showed positivity, whereas
expression was weaker for claudin-10, which showed 24%
of cases positive, and for claudin-17, which showed 18% of
cases positive. In accordance with this, we also observed
lower E-cadherin expression in diffuse carcinomas. It
might also be that loss of claudins and E-cadherin expres-
sion is somehow interrelated in as much as E-cadherin
has been shown to influence the formation of tight junc-
tions and desmosomes although it mainly mediates the as-
sembly of adherents junctions. In line with this, there was
an association between expression of claudins-4 and −5
and E-cadherin [43]. However, little data are available on
the functional association between E-cadherin and clau-
dins at present. Several proteins were identified that were
associated with prognosis of the gastric cancer patients,
for instance, It is reported that Astragalus saponins inhib-
ited human gastric cancer cell growth, decreased the inva-
sion ability and induced the apoptosis and Variable copy
number of mitochondrial DNA (mtDNA) predicts worse
prognosis in advanced gastric cancer patients [44,45]. In
addition to this, inducible nitric oxide synthase expression
in gastric adenocarcinoma related with lymph angiogen-
esis and lymphatic metastasis and the expression of
TIMP3 gene may provide evidence for the molecular diag-
nosis and stage evaluation of gastric cancer [46,47]. Our
data revealed that E-cadherin expression has been associ-
ated with a poorer prognosis of the patients. In general,
such an association could not be seen with claudins, ex-
cept for claudin-3, where its lowered expression was asso-
ciated with a marginally poorer prognosis [48].
In conclusion, our present data observes tight junction
proteins claudins-10, -14, -17 and E-cadherin between hu-
man gastric cancers and adjacent non-neoplastic tissues
correlate with lymph node metastasis. In addition, claudin-
10, claudin-17 and E-cadherin. In this respect, the loss ofudin-14 and claudin-17
P CLAUDIN-14(+) CLAUDIN-14(−) φ* P
<0.01 5 4 0.124 0.695
24 17
0.516
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and together with this molecule, might contribute to the
loose cell cohesion in gastric cancer.
Conclusion
The present work infers that the expression altered of
claudin-10, claudin-14, claudin-17 and E-cadherin be-
tween human gastric cancers and adjacent non-neoplastic
tissues correlate with lymph node metastasis. In addition,
claudin-10, claudin-17 and E-cadherin were concurrently
expressed in gastric cancer. However, the specific mechan-
ism responsible for these observations needs to be
addressed in the future.
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